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Dear Editor,
We read with great interest the article by Hossain et al., in
April 2013 ‘‘Is discontinuation of clopidogrel necessary for
intracapsular hip fracture surgery? Analysis of 102 hemi-
arthroplasties’’. An increasing number of patients present-
ing for anesthesia are taking clopidogrel and an even
greater number are on combination antiplatelet therapies,
potentially increasing the risk of intraoperative and peri-
operative bleeding.
Hossain et al. [1] found no increase in complications or
transfusions in patients with perioperative clopidogrel and
those without. Collyer et al. [2], conducted a similar study
on 114 patients receiving regular clopidogrel therapy and
presenting for urgent hip fracture surgery. While an
increased risk of requiring blood transfusion during or after
surgery was noted in patients off clopidogrel for only
1 day, no major complications were reported.
It is our opinion that correlation between platelet func-
tion and responsiveness to clopidogrel is of paramount
importance. There is significant individuality in patient
responsiveness to clopidogrel, suggesting that an individ-
ualized, evidence-based approach is needed to assess the
risk of adverse outcomes in patients receiving regular
clopidogrel therapy. We suggest the use of the Thrombe-
lastograph  Platelet Mapping
TM
(TEG-PM) assay for pre-
operative assessment of platelet ADP receptor inhibition.
Collyer et al. [2, 3], provided insight to weak and unpre-
dictable responses to clopidogrel therapy and the risk of
acute coronary syndrome in patients off clopidogrel for
more than 4 days. This emphasizes the importance of
measuring platelet function to determine residual clopido-
grel therapy.
We assessed the ability of TEG-PM to detect preoper-
ative platelet function secondary to clopidogrel and/or
aspirin therapy [4]. In an expansion of the study, we
assessed preoperative platelet function in 131 patients
based on days off of clopidogrel and/or aspirin on the day
of surgery. Of the 131, 16 patients were followed contin-
uously from the time of their preoperative anesthesia clinic
visit to the day of surgery (Fig. 1; Table 1).
Two important findings were: (1) a trend towards
platelet recovery by day 5 off clopidogrel, (2) 60 % of the
patient population were not effectively inhibited while on
therapy [4]. In a prospective observational study of 59
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Fig. 1 Whisker plot distribution comparing anesthesia clinic and
preoperative percent (%) ADP inhibition in 16 patients based on days
off clopidogrel. Anesthesia clinic values are presented in red while
preoperative values are presented in green
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patients, Collyer et al. [3] also observed a decline in %
ADP inhibition with longer interruption of clopidogrel as
well as inconsistent efficacy of clopidogrel to inhibit
platelet function. Our findings suggest that a preoperative
TEG-PM assay might be a feasible approach to objectively
evaluate effects of clopidogrel during the perioperative
period, guide drug management and avoid adverse out-
comes related to hypercoagulability and thrombosis as well
as increased bleeding risk. We recommend a larger study
correlating TEG-PM values with the incidence of compli-
cations and transfusions in older patients presenting for
urgent hip fracture surgery.
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Table 1 Anesthesia clinic and preoperative percent (%) platelet
inhibition (mean ± SD) in 16 patients separated into three groups by
their days off of clopidogrel (\3, 3–5 and [5 days)
Days off of
clopidogrel




Mean Median Mean Median
\3 days 7 54.8 ± 25.8 49.3
(37.6,
66.8)
48.7 ± 35.8 34.4
(24.7,
74.8)
3–5 days 7 44.8 ± 34.9 46.0
(17.8,
64.9)
20.4 ± 17.7 12.7
(6.6,
35.1)
[5 days 2 49.4 ± 45.0 49.4
(33.5,
65.3)





16 49.7 ± 30.2 47.7
(23.7,
73.9)
32.8 ± 29.6 26.4
(8.8,
44.0)
Data are presented as mean ± SD, and median (1st and 3rd quartile)
SD standard deviation, ADP adenosine diphosphate
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